Expert Perspectives on Clinical Practice

Daily Clinical Updates & Downloadable Slides from the 2011 Connective Tissue Oncology Meeting in Chicago

	Expert Interviews
	Downloadable slides

Release Date
October 31, 2011

Expiration Date
October 31, 2012

Faculty

George Demetri, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Piotr Rutkowski, MD, PhD
Maria Sklodowska-Curie Memorial Cancer Center
Warsaw, Poland

Target Audience
This educational activity is designed for physicians and other healthcare providers involved in the care of patients with sarcoma.

Overview
This CME-certified interview discusses recently released data from the 2011 Connective Tissue Oncology Meeting in Chicago.

Learning Objectives
After successful completion of this educational activity, participants should be able to:

Discuss the utility of targeted therapies for soft tissue sarcoma and gastrointestinal stromal tumors (GIST)
Explain the rationale for identifying predictive markers for targeted therapies in sarcoma
Analyze recent data regarding predictive markers for response to sarcoma therapy, with a focus on how these data might be utilized to guide therapy selection in clinical practice

Sponsorship
This activity is sponsored by prIME Oncology.

Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.

Links to the post test are available on the video player page.

Support Statements
Support for this educational activity is provided by Merck & Co. Inc.

Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Faculty Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Demetri has disclosed that he has received consulting fees from Novartis, Pfizer, Johnson & Johnson, GlaxoSmithKline, Amgen, Merck, Daiichi-Sankyo, Millenium/Takeda, Sanofi, and ZioPharm. He has received consulting fees and also has ownership interest in Plexxikon, Nereus, N-of-One, Champions Biotechnology, Kolltan Pharmaceuticals, EmergingMed.com, and Collabrx.com. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rutkowski has disclosed that he has received consulting fees from Novartis and MSD, and fees for non-CME services from Novartis and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

Chelsey Goins, PhD (clinical) – no relevant financial relationships to disclose
Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose

Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.